Ryan Alexander Jones - 28 May 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role: Chief Financial Officer
Signature: By: /s/ Ryan Jones
Issuer symbol: KYTX
Transactions as of: 28 May 2024
Net transactions value: +$13,152
Form type: 4
Filing time: 29 May 2024, 16:33:20 UTC
Previous filing: 07 Feb 2024
Next filing: 15 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYTX	Common Stock	Options Exercise	$7,935	+10,870	+42%	$0.7300^*	36,804	28 May 2024	Direct	F1
transaction	KYTX	Common Stock	Options Exercise	$5,217	+7,146	+19%	$0.7300^*	43,950	28 May 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYTX	Stock Option (Right to Buy)	Options Exercise	$0	-10,870	-100%	$0.000000^*	0	28 May 2024	Common Stock	10,870	$0.7300	Direct	F1
transaction	KYTX	Stock Option (Right to Buy)	Options Exercise	$0	-7,146	-77%	$0.000000	2,192	28 May 2024	Common Stock	7,146	$0.7300	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter.
F2	25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.